Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash from Operations (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Cash from Operations data on record, last reported at 26963000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations rose 38.78% year-over-year to 26963000.0; the TTM value through Sep 2025 reached 134009000.0, up 21.98%, while the annual FY2024 figure was 170860000.0, 17.79% up from the prior year.
  • Cash from Operations reached 26963000.0 in Q3 2025 per ZNTL's latest filing, up from 34708000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 26963000.0 in Q3 2025 and bottomed at 79275000.0 in Q2 2023.
  • Average Cash from Operations over 4 years is 42449333.33, with a median of 39702000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: plummeted 84.24% in 2023, then soared 55.67% in 2024.
  • A 4-year view of Cash from Operations shows it stood at 37329000.0 in 2022, then fell by 8.76% to 40599000.0 in 2023, then rose by 2.21% to 39702000.0 in 2024, then surged by 32.09% to 26963000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 26963000.0 in Q3 2025, 34708000.0 in Q2 2025, and 32636000.0 in Q1 2025.